Literature DB >> 25789231

Optimized and Validated RP-UPLC Method for the Determination of Losartan Potassium and Chlorthalidone in Pharmaceutical Formulations.

Tadiboyina Sirisha1, Bannimath Gurupadayya1, Sridhar Siddiraju2.   

Abstract

PURPOSE: A validated ultra performance liquid chromatography (UPLC) method has been developed and validated for the simultaneous determination of losartan potassium and chlorthalidone in pharmaceutical preparations.
METHODS: Waters-Acquity UPLC system equipped with Auto Sampler, PDA detector and operated with Empower-2 software was used for the present study. Detection was done at wavelength of 230 nm, HSS C18, 100 mm x 2.1x 1.8 μm column with a reverse phase elution and mobile phase composed of A and B mixed in the ratio 56:44 v/v (Where mobile phase A consists of potassium dihydrogen phosphate buffer of pH 3.0 and Mobile phase B consists of acetonitrile and methanol mixed in the ratio of 90:10 v/v) used at a flow rate of 0.4ml per minute.
RESULTS: The retention times for losartan potassium and chlorthalidone were observed at 0.72 and 1.89 minutes. The developed method was validated as per ICH guidelines. Linearity ranges were found to be 12.5-125 μg/ml and 3.125-31.25 μg/ml for losartan potassium and chlorthalidone, respectively.
CONCLUSION: This method is fast, accurate, precise and sensitive hence it can be employed for routine quality control of tablets containing both drugs in industries.

Entities:  

Keywords:  Chlorthalidone; Chromatography; Losartan

Year:  2015        PMID: 25789231      PMCID: PMC4352217          DOI: 10.5681/apb.2015.019

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  8 in total

1.  Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets.

Authors:  Olga C Lastra; Igor G Lemus; Hugo J Sánchez; Renato F Pérez
Journal:  J Pharm Biomed Anal       Date:  2003-09-19       Impact factor: 3.935

2.  Simultaneous determination of atenolol, chlorthalidone and amiloride in pharmaceutical preparations by capillary zone electrophoresis with ultraviolet detection.

Authors:  Khaldun M Al Azzam; Bahruddin Saad; Hassan Y Aboul-Enein
Journal:  Biomed Chromatogr       Date:  2010-09       Impact factor: 1.902

3.  Differential potentiometric method for determining dissociation constants of very slightly water-soluble drugs applied to the sulfonamide diuretic chlorthalidone.

Authors:  H L Fleuren; C A van Ginneken; J M van Rossum
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

4.  Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Authors:  Pedro Dorado; Esther Machín; Fernando de Andrés; María-Eugenia Naranjo; Eva M Peñas-Lledó; Adrián Llerena
Journal:  Drug Metabol Drug Interact       Date:  2012

5.  Determination of losartan and triamterene in pharmaceutical compounds and urine using cathodic adsorptive stripping voltammetry.

Authors:  Ali Asghar Ensafi; Reza Hajian
Journal:  Anal Sci       Date:  2008       Impact factor: 2.081

6.  Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS.

Authors:  Hiten J Shah; Mohan L Kundlik; Nitesh K Patel; Gunta Subbaiah; Dasharath M Patel; Bhanubhai N Suhagia; Chhagan N Patel
Journal:  J Sep Sci       Date:  2009-10       Impact factor: 3.645

7.  Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics.

Authors:  Myriam C Salvadori; Roberto F Moreira; Bruno C Borges; Maristela H Andraus; Cristina P Azevedo; Ronilson A Moreno; Ney C Borges
Journal:  Clin Exp Hypertens       Date:  2009-07       Impact factor: 1.749

8.  Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.

Authors:  Vijaya Kumari Karra; Nageswara Rao Pilli; Jaswanth Kumar Inamadugu; J V L N Seshagiri Rao
Journal:  Pharm Methods       Date:  2012-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.